Page 162 - Read Online

Sullivan et al. Hepatoma Res 2018;4:68 I http://dx.doi.org/10.20517/2394-5079.2018.95 Page 9 of 10

hepatocellular carcinoma: analysis of prognostic factors. J Hepatol 2013;58:89-97.
20. Lencioni R, Cioni D, Crocetti L, Franchini C, Pina CD, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term
results of percutaneous image-guided radiofrequency ablation. Radiology 2005;234:961-7.
21. Lee DH, Lee JM, Lee JY, Kim SH, Yoon JH, et al. Radiofrequency ablation of hepatocellular carcinoma as first-line treatment: long-term
results and prognostic factors in 162 patients with cirrhosis. Radiology 2014;270:900-9.
22. N’Kontchou G, Mahamoudi A, Aout M, Ganne-Carrié N, Grando V, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term
results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009;50:1475-83.
23. Francica G, Saviano A, De Sio I, De Matthaeis N, Brunello F, et al. Long-term effectiveness of radiofrequency ablation for solitary small
hepatocellular carcinoma: a retrospective analysis of 363 patients. Dig Liver Dis 2013;45:336-41.
24. Brunello F, Cantamessa A, Gaia S, Carucci P, Rolle E, et al. Radiofrequency ablation: technical and clinical long-term outcomes for single
hepatocellular carcinoma up to 30 mm. Eur J Gastroen Hepat 2013;25:842-9.
25. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for
hepatocellular carcinoma < or =4 cm. Gastroenterology 2004;127:1714-23.
26. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation,
percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut
2005;54:1151-6.
27. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for
small hepatocellular carcinoma. Gastroenterology 2005;129:122-30.
28. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of
radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228:235-40.
29. Abdelaziz A, Elbaz T, Shousha HI, Mahmoud S, Ibrahim M, et al. Efficacy and survival analysis of percutaneous radiofrequency versus
microwave ablation for hepatocellular carcinoma: an Egyptian multidisciplinary clinic experience. Surg Endosc 2014;28:3429-34.
30. Shibata T, Iimuro Y, Yamamoto Y, Maetani Y, Ametani F, et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and
percutaneous microwave coagulation therapy. Radiology 2002;223:331-7.
31. Cannon R, Ellis S, Hayes D, Narayanan G, Martin RC, 2nd. Safety and early efficacy of irreversible electroporation for hepatic tumors in
proximity to vital structures. J Surg Oncol 2013;107:544-9.
32. Sutter O, Calvo J, N’Kontchou G, Nault JC, Ourabia R, et al. Safety and efficacy of irreversible electroporation for the treatment
of hepatocellular carcinoma not amenable to thermal ablation techniques: a retrospective single-center case series. Radiology
2017;284:877-86.
33. Fruhling P, Nilsson A, Duraj F, Haglund U, Noren A. Single-center nonrandomized clinical trial to assess the safety and efficacy of
irreversible electroporation (IRE) ablation of liver tumors in humans: Short to mid-term results. Eur J Surg Oncol 2017;43:751-7.
34. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
35. Llovet JM, Real MI, Montana X, Planas R, Coll S, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in
patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9.
36. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable
hepatocellular carcinoma. Hepatology 2002;35:1164-71.
37. Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin
microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised
controlled phase 3 trial. Lancet Oncol 2017;18:1624-36.
38. Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, et al. SIRveNIB: selective internal radiation therapy Versus Sorafenib in Asia-
Pacific patients with hepatocellular carcinoma. J Clin Oncol 2018; doi: 10.1200/jco.2017.76.0892:Jco2017760892.
39. McDevitt JL, Alian A, Kapoor B, Bennett S, Gill A, et al. Single-center comparison of overall survival and toxicities in patients with
infiltrative hepatocellular carcinoma treated with Yttrium-90 radioembolization or drug-eluting embolic transarterial chemoembolization. J
Vasc Interv Radiol 2017;28:1371-7.
40. Akinwande O, Kim D, Edwards J, Brown R, Philips P, et al. Is radioembolization ((90)Y) better than doxorubicin drug eluting beads
(DEBDOX) for hepatocellular carcinoma with portal vein thrombosis? A retrospective analysis. Surg Oncol 2015;24:270-5.
41. Moreno-Luna LE, Yang JD, Sanchez W, Paz-Fumagalli R, Harnois DM, et al. Efficacy and safety of transarterial radioembolization versus
chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol 2013;36:714-23.
42. Lance C, McLennan G, Obuchowski N, Cheah G, Levitin A, et al. Comparative analysis of the safety and efficacy of transcatheter arterial
chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol
2011;22:1697-705.
43. Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, et al. Y90 radioembolization significantly prolongs time to progression compared with
chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2016;151:1155-63.e2.
44. Kooby DA, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, et al. Comparison of yttrium-90 radioembolization and transcatheter
arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2010;21:224-30.
45. Padia SA, Johnson GE, Horton KJ, Ingraham CR, Kogut MJ, et al. Segmental Yttrium-90 radioembolization versus segmental
chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study. J Vasc
Interv Radiol 2017;28:777-85.e1.
46. Katsanos K, Kitrou P, Spiliopoulos S, Maroulis I, Petsas T, et al. Comparative effectiveness of different transarterial embolization therapies
alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: a network meta-
analysis of randomized controlled trials. PLoS One 2017;12:e0184597.
47. Kang JK, Kim MS, Cho CK, Yang KM, Yoo HJ, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local
salvage treatment after incomplete transarterial chemoembolization. Cancer 2012;118:5424-31.
48. Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced